BEIJING, Nov. 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical productsin China, announced today that management is scheduled to present at the Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 8 a.m. Eastern time.
A live webcast of the presentation will be available online on the Investor Relations home page of Sinovac's corporate Web site at http://www.sinovac.com .
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: firstname.lastname@example.org Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: email@example.com firstname.lastname@example.org Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: email@example.com
SOURCE Sinovac Biotech Ltd.
Subscribe to our Free Newsletters!
Immunotherapy is a type of treatment method that works by using certain components of a person's ...
Elderberry and its other plant parts provide an array of health benefits. Know how this fruit helps ...
Increasing weight and obesity are some of the most common health problems today. A smart weight ...View All